Lazertinib: First Approval
- PMID:34028784
- PMCID: PMC8217052
- DOI: 10.1007/s40265-021-01533-x
Lazertinib: First Approval
Erratum in
- Correction to: Lazertinib: First Approval.Dhillon S.Dhillon S.Drugs. 2021 Jul;81(10):1241. doi: 10.1007/s40265-021-01549-3.Drugs. 2021.PMID:34106457Free PMC article.No abstract available.
Abstract
Lazertinib (LECLAZA®) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). It is a brain-penetrant, irreversible EGFR-TKI that targets the T790M mutation and activating EGFR mutations Ex19del and L858R, while sparing wild type-EGFR. In January 2021, lazertinib received its first approval for the treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC who have previously received EGFR-TKI therapy. This article summarizes the milestones in the development of lazertinib leading to this first approval.
Conflict of interest statement
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Figures
Similar articles
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC.Ahn MJ, et al.Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3.Lancet Oncol. 2019.PMID:31587882Clinical Trial.
- EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ.Park S, et al.Cancer Res Treat. 2020 Oct;52(4):1288-1290. doi: 10.4143/crt.2020.278. Epub 2020 Jun 22.Cancer Res Treat. 2020.PMID:32599977Free PMC article.
- A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ.Cho BC, et al.J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24.J Thorac Oncol. 2022.PMID:34958928Clinical Trial.
- Furmonertinib: First Approval.Deeks ED.Deeks ED.Drugs. 2021 Oct;81(15):1775-1780. doi: 10.1007/s40265-021-01588-w.Drugs. 2021.PMID:34528187Review.
- Lazertinib: on the Way to Its Throne.Lee J, Hong MH, Cho BC.Lee J, et al.Yonsei Med J. 2022 Sep;63(9):799-805. doi: 10.3349/ymj.2022.63.9.799.Yonsei Med J. 2022.PMID:36031779Free PMC article.Review.
Cited by
- Role of protein phosphorylation in cell signaling, disease, and the intervention therapy.Pang K, Wang W, Qin JX, Shi ZD, Hao L, Ma YY, Xu H, Wu ZX, Pan D, Chen ZS, Han CH.Pang K, et al.MedComm (2020). 2022 Nov 3;3(4):e175. doi: 10.1002/mco2.175. eCollection 2022 Dec.MedComm (2020). 2022.PMID:36349142Free PMC article.Review.
- Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.Boch T, Köhler J, Janning M, Loges S.Boch T, et al.Cancer Biol Med. 2022 Dec 5;19(11):1543-64. doi: 10.20892/j.issn.2095-3941.2022.0540.Cancer Biol Med. 2022.PMID:36476337Free PMC article.Review.
- The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.Nitulescu GM, Stancov G, Seremet OC, Nitulescu G, Mihai DP, Duta-Bratu CG, Barbuceanu SF, Olaru OT.Nitulescu GM, et al.Molecules. 2023 Jul 12;28(14):5359. doi: 10.3390/molecules28145359.Molecules. 2023.PMID:37513232Free PMC article.Review.
- Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control.Jeon HL, Kwak M, Kim S, Yu HY, Shin JY, Jung HA.Jeon HL, et al.Sci Rep. 2024 Jun 25;14(1):14659. doi: 10.1038/s41598-024-65220-z.Sci Rep. 2024.PMID:38918528Free PMC article.
- Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy.Wang YT, Yang PC, Zhang JY, Sun JF.Wang YT, et al.Molecules. 2024 Mar 23;29(7):1448. doi: 10.3390/molecules29071448.Molecules. 2024.PMID:38611728Free PMC article.Review.
References
- Lim J-Y. Yuhan’s lung cancer treatment lazertinib wins approval [media release]. 18 Jan 2021.http://www.koreaherald.com/view.php?ud=20210118001003.
- Ministry of Food and Drug Safety Republic of Korea. LECLAZA (lazertinib): Republic of Korea prescribing information. 2021.https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=202100467. Accessed 11 Apr 2021.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous